Majid YAGHOUBI-ASHRAFI, Akbar HEDAYATIZADEH-OMRAN, Zainab QAZIZADEH, Razieh-Sadat MOUSAVI, Ramin SHEKARRIZ, Mohammad ESLAMI, Ehsan ZABOLI, Ghasem JANBABAEI, Mohsen AARABI, Reza ALIZADEH-NAVAEI, Mahmood MOOSAZADEH

Epidemiology of Gastrointestinal Cancers in the North of Iran: Results of Mazandaran Population-BasedCancer Registry

Although initial pathological studies indicate the high prevalence of gastrointestinal cancers in northern Iran, to our knowledge, no population-based cancer registry studies have been conducted on gastrointestinal cancers. Hence, the present research aimed to review the epidemiologic status of gastrointestinal cancers in northern Iran region using the population-based cancer registry data.METHODSThis cross-sectional study was conducted on 4460 subjects in the Mazandaran Population-Based Cancer Registry, which is located in the North of Iran. Among gastrointestinal cancers diagnosed between 2014 and 2015, cancers with codes C15 to C26 were collected. Age-standardized incidence rate (ASR) (per 100,000 person-years) were calculated as standardized to the world standard population using the direct standardization method. RESULTSThis study results showed that a total of 1318 (29.5%) people were afflicted with gastrointestinal cancers in the studied area, the most prevalent of which included gastric cancer (44.2%), colorectal cancer (27.2%), and esophageal cancer (13.5%). The mean age of the subjects was 66.15±14.7, and 804 of them (61%) were male. ASR in men and women was equal to 5.56 and 4.03 for esophageal cancer, 20.44 and 10.14 for gastric cancer, 1.61 and 1.4 for pancreatic cancer, and 10.86 and 8.74 for colorectal cancer and there was a significancant difference (p=0.008) for sex distribution in these cancers.CONCLUSIONThe findings obtained in this study suggested that gastrointestinal cancers account for a substantial percentage of cancers in northern Iran and that gastric cancer is the most prevalent type of gastrointestinal cancers in this region.

PDF

___

1. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol 2012;13(8):790–801.
2. Lee SG, Kim B, Yook JH, Oh ST, Lee I, Song K. TNF/ LTA polymorphisms and risk for gastric cancer/ duodenal ulcer in the Korean population. Cytokine 2004;28(2):75–82.
3. Naghavi M, Abolhassani F, Pourmalek F, Lakeh M, Jafari N, Vaseghi S, et al. The burden of disease and injury in Iran 2003. Popul Health Metr 2009;7:9.
4. Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Ann Oncol. 2009;20(3):556-563.
5. Mousavi SM, Alamolhoda AA, Gouya MM, Lickiss N. Implementation of Comprehensive National Cancer Control Program in Iran: an experience in a developing country. Ann Oncol 2008;19(2):398–400.
6. Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E, et al. Recent patterns in gastric cancer: a global overview. Int J Cancer 2009;125(3):666–73.
7. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet 2009;374(9688):477–90.
8. Sadjadi A, Malekzadeh R, Derakhshan MH, Sepehr A, Nouraie M, Sotoudeh M, et al. Cancer occurrence in Ardabil: results of a population-based cancer registry from Iran. Int J Cancer 2003;107(1):113–8.
9. Malekzadeh R, Derakhshan MH, Malekzadeh Z. Gastric cancer in Iran: epidemiology and risk factors. Arch Iran Med 2009;12(6):576–83.
10. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136(5):E359–86.
11.Lafaro KJ, Demirjian AN, Pawlik TM. Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am 2015;24(1):1–17.
12.Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010;42 Suppl 3(Suppl 3):S206–14.
13.Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2015;385(9972):977–1010.
14.Haghdoust AA, Chamani G, Zarei MR, Rad M, Hashemipour M, Marzban M. Low incidence of colorectal cancer in Kerman province, Iran. Iranian journal of cancer prevention. 2011; 4(1): 33–7.
15.Saberi-Firoozi M, Kamali D, Yousefi M, Mehrabani D, Khademolhosseini F, Heydari S, et al. Clinical characteristics of colorectal cancer in Southern Iran, 2005. Iran Red Crescent Med J 2007;9(4):209–11.
16.Abdifard E, Ghaderi S, Hosseini S, Heidari M. Incidence trends of colorectal cancer in the West of Iran during 2000-2005. Asian Pac J Cancer Prev 2013;14(3):1807–11.
17.Wistuba II, Gazdar AF. Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer. 2004 Sep;4(9):695–706.
18.Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol 2014;6:99–109.
19.Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013 Feb 2;381(9864):400-12.
20.Umar SB, Fleischer DE. Esophageal cancer: epidemiology, pathogenesis and prevention. Nat Clin Pract Gastroenterol Hepatol 2008;5(9):517–26.
21.Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol 2013;19(34):5598–606.
22.Chong VH, Telisinghe PU, Chong CF. Esophageal Cancer in Brunei Darussalam over a three Decade Period: an Epidemiologic Study of Trends and Differences between Genders and Racial Groups. Asian Pac J Cancer Prev 2015;16(9):4123–6.
23.Mao WM, Zheng WH, Ling ZQ. Epidemiologic risk factors for esophageal cancer development. Asian Pac J Cancer Prev 2011;12(10):2461–6.
24.Wu M, Zhao JK, Hu XS, Wang PH, Qin Y, Lu YC, et al. Association of smoking, alcohol drinking and dietary factors with esophageal cancer in high- and low-risk areas of Jiangsu Province, China. World J Gastroenterol 2006;12(11):1686–93.
25.Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2013. National Cancer Institute. Available at: https://seer.cancer.gov/archive/csr/1975_2013/ Accessed Aug 26, 2020.
26.Hidalgo M, Cascinu S, Kleeff J, Labianca R, Löhr JM, Neoptolemos J, et al. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology 2015;15(1):8–18.
27.Pourhoseingholi MA, Ashtari S, Hajizadeh N, Fazeli Z, Zali MR. Systematic review of pancreatic cancer epidemiology in Asia-Pacific Region: major patterns in GLOBACON 2012. Gastroenterol Hepatol Bed Bench. 2017;10(4): 245–57.
28.Mohebbi M, Mahmoodi M, Wolfe R, Nourijelyani K, Mohammad K, Zeraati H, et al. Geographical spread of gastrointestinal tract cancer incidence in the Caspian Sea region of Iran: spatial analysis of cancer registry data. BMC Cancer 2008;8:137.
29.Yazdani-Charati J, Janbabaei G, Etemadinejad S, Sadeghi S, Haghighi F. Survival of patients with stomach adenocarcinoma in North of Iran. Gastroenterol Hepatol Bed Bench 2014;7(4):211–7.
30.Mortazavi S, Niroomand-Rad A, Roshan-Shomal P, Razavi-Toosi S, Mossayeb-Zadeh M, Moghadam M. Does short-term exposure to elevated levels of natural gamma radiation in Ramsar cause oxidative stress? Int J Appl Basic Med Res 2014;4(2):72–6.
31.Somi MH, Golzari M, Farhang S, Naghashi S, Abdollahi L. Gastrointestinal cancer incidence in East Azerbaijan, Iran: update on 5 year incidence and trends. Asian Pac J Cancer Prev 2014;15(9):3945–9.
32.Sierra MS, Cueva P, Bravo LE, Forman D. Stomach cancer burden in Central and South America. Cancer Epidemiol 2016;44 Suppl 1:62–73.
33.Bazarbashi S, Al Eid H, Minguet J. Cancer Incidence in Saudi Arabia: 2012 Data from the Saudi Cancer Registry. Asian Pac J Cancer Prev 2017;18(9):2437–44.
34. Zhao J, He YT, Zheng RS, Zhang SW, Chen WQ. Analysis of esophageal cancer time trends in China, 1989- 2008. Asian Pac J Cancer Prev 2012;13(9):4613–7.
35.Cheng ML, Zhang L, Borok M, Chokunonga E, Dzamamala C, Korir A, et al. The incidence of oesophageal cancer in Eastern Africa: identification of a new geographic hot spot? Cancer Epidemiol 2015;39(2):143–9.
36.Chen W, Zheng R, Zeng H, Zhang S. The updated incidences and mortalities of major cancers in China, 2011. Chin J Cancer 2015;34(11):502–7.
37.Bray F, Parkin DM. Evaluation of data quality in the cancer registry: principles and methods. Part I: comparability, validity and timeliness. Eur J Cancer 2009;45(5):747–55.
38.Matsuda A, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H, et al. Cancer incidence and incidence rates in Japan in 2008: a study of 25 population based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 2014;44(4):388–96.
39.Larsen IK, Småstuen M, Johannesen TB, Langmark F, Parkin DM, Bray F, et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer 2009;45(7):1218–31.
40.Garrido DI, Garrido SM. Cancer risk associated with living at high altitude in Ecuadorian population from 2005 to 2014. Clujul Med 2018;91(2):188–196.
41.Akan Z, Baskurt B, Asliyuksek H, Kam E, Yilmaz A, Yuksel MB, et al. Environmental radioactivity and high incidence rates of stomach and esophagus cancer in the Van Lake region: a causal relationship? Asian Pac J Cancer Prev 2014;15(1):375–80.